Shanghai, China, November 28,2020 – Asieris Pharmaceuticals today announced it has been awarded “the Top 100 China Innovative Pharmaceutical Enterprises” at the 2020 Hangzhou China Healthcare Summit of Entrepreneurs, Scientists and Investors. Among this prestigious list, Asieris Pharmaceuticals is the only China-based, globally oriented company specializing in the R&D of new drugs for the treatment of genitourinary and gynecological diseases, and was also invited to the awarding ceremony.
The award is another testimony to our pharmaceutical research and development capability. With focus on genitourinary and gynecological diseases, our goal is to establish a leading position in this field with unique strategies. One of our major products is APL-1202. It is also the first oral selective human methionine aminopeptidases II (MetAP2) inhibitor in phase III clinical trial in the world. Another leading product, APL-1702 (Cevira®), is a photodynamic drug-device combination product, and is currently being developed for the non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL). Its global, multi-centered Phase III clinical trial has been approved and the first patient was enrolled on November 11, 2020.
About Asieris Pharmaceuticals
Asieris Pharmaceuticals was founded inside the ‘China Medical City’ located in the city of Taizhou, Jiangsu Province, PRC, in March 2010. Asieris is determined to become a leading pharmaceutical company driven by innovative technologies and products that focus on genitourinary and gynecological diseases. The company and its professional teams are located in Shanghai, Beijing, Taizhou, the US, and the UK, with their research and development center in Jinqiao District, Shanghai.
Asieris adheres to the growth model of proprietary R&D supplemented by in-licensing, to rapidly establish leadership in their focused fields with in-depth strategic plans. We create global values with our first-in-class innovative drugs with breakthrough potentials. Meanwhile, we have unique R&D platforms for anti-tumor and anti-microbial resistance drugs. In addition, we in-license late-development stage and marketed products for the Chinese market to enhance our pipeline and to quickly establish our leadership position in the domestic market.